Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
NCT05542407Phase 1Recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Oct 2023
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of dordaviprone and atezolizumab in endometrial cancer (EC) (2 arms), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Recommended Phase 2 Dose at 3 weeks. Started Oct 2023; status: recruiting.
02
Drugs
dordaviproneatezolizumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05542407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05542407.